INTRODUCTION

1
The Gram-negative bacterium, Francisella tularensis, is the etiological agent of the disease insights into the role of CD4 + T cells in immunity to F. tularensis, no such tool currently exists 9 6
to characterize CD8 + T cells, which are also required for protection against this predominantly 9 7 intracellular pathogen [12, 19, 20] . To address this shortcoming, we have developed a tool for expression of chicken ovalbumin transgenic) CD8 + T cells [23] , which can be adoptively transferred into congenic C57BL/6 mice.
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Here we report the development of this tool and a proof-of-concept study using OVA-expressing 1 0 3
F. tularensis LVS (termed LVS-OVA)
. In response to LVS-OVA, OT-I CD8 + T cells proliferate,
differentiate into effector and central memory subsets, and produce interferon gamma (IFN-γ).
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We also compare how these cells respond following intranasal or scarification vaccination with 1 0 6 LVS-OVA, followed by an intranasal booster. This novel tool will enable further detailed studies 1 0 7
into the CD8 + T cell response to F. tularensis. propensity for effector functions, including killing infected cells and producing cytokines. effector cells upon re-exposure to antigen [42, 43] . Using our model, we monitored the
MATERIALS AND METHODS
Francisella-specific T EM and T CM subsets that arose in the lungs, MLN and spleen in response to
intranasal LVS-OVA infection. In the lungs, the highest number of effector memory OT-I cells were observed on day 7 (Fig 5B) ,
which coincides with the peak bacterial burden in this assay ( Fig 3A) . T EM remained at high number detected on d28 post-infection. In the MLN, T EM numbers followed a similar general
pattern as in the lung, with the most cells present on day 7; however, a transient increase was
observed on day 28, possibly reflecting egress of these cells out of the lung (Fig 5B) . In contrast
to the lungs and MLN, T EM peaked in number on day 14 in the spleen (Fig 5B) . This may be due
to the fact that bacteria reach the spleen and replicate later in the course of pneumonic tularemia
compared to the lungs (Fig 3A and [44, 45] ). Consistent with the data for total OT-I cells (Fig 3) ,
Francisella-specific T EM are retained well in the spleen and poorly in the lungs after bacterial 3 5 8
clearance. day7, † day 14, ‡ day 21. As expected, the number of T CM in the lung was much lower than the number of T EM during 3 6 8 infection, and remained similar from day 7 to day 28 ( Fig 5C) . The number of T CM in the MLN 3 6 9 peaked on day 14, then exhibited a trend towards gradual decrease over time. In the spleen, T CM 3 7 0 increased in number between day 7 and 21, and decreased on day 28 ( Fig 5C) . These data show 3 7 1 that our LVS-OVA/OT-I model can be used to monitor Francisella-specific CD8 + T cell 3 7 2 memory subsets, and that these subsets show disparate expansion, contraction and retention
properties in various tissues following intranasal LVS infection. Comparison of Francisella-specific CD8 + T cell responses to scarification-prime, intranasal
boost-versus intranasal-prime, intranasal-boost vaccination strategies
To demonstrate one potential application of LVS-OVA, we studied CD8 + T cell responses in 3 7 8 mice primed either intranasally or via scarification, both followed by an intranasal booster.
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Responses were assessed on day 28 after primary vaccination, and also three and five days after
an intranasal booster given on day 30. Mice primed by the intranasal route exhibited significant
weight loss before recovering, while mice primed via scarification did not lose weight (Fig 6A) .
The intranasal booster was well tolerated by both groups (Fig 6B and Fig S1) . On day 28 post-
vaccination, similar numbers of OT-I cells were present in the lungs and spleens of both groups 3 8 4
( Fig 6C) . The MLNs of animals given the intranasal primary vaccination harbored more OT-I 3 8 5 cells at this point (Fig 6C) . The intranasal booster increased the number of OT-I cells in the
MLNs of scarification-primed mice, such that they matched intranasally-primed mice.
Additionally, the number of Francisella-specific cells in the lungs of scarification-primed mice 3 8 8
increased after the booster, reaching significantly higher levels than in intranasally-primed and 3 8 9 boosted mice. A similar trend was observed for the numbers of Francisella-specific T EM and T CM 3 9 0 cells following priming and booster in both schemes of vaccination (Fig 6D-E) . Finally, we within the lungs after these vaccination schemes (Fig 7) . For all animals, very few CD69 leads to more Francisella-specific CD8 + T cells in the MLN compared to scarification vaccination; 2) an intranasal booster increases the number of Francisella-specific CD8 + cells in the MLN and lung of scarification-primed animals, while avoiding the weight loss associated with intranasal primary vaccination; and 3) neither regimen appears to effectively elicit
Francisella-specific lung-resident CD8 + T cells. significance was determined by two-tailed, unpaired t-test at each timepoint * p<0.05 ** p<0.01. according to two-tailed, unpaired t-tests. There is currently no approved vaccine for the prevention of tularemia, due to concerns expressing it as a C-terminal tag of the native VgrG protein did we achieve a robust expression 4 2 7
( Fig 1A-B) . A strain of F. tularensis LVS containing our expression construct (LVS-OVA) adoptively-transferred CD8 + OT-I cells in infected mice. We first sought to study the initial expansion of F. tularensis-specific CD8 + T cells after innate pro-inflammatory pathways early in the course of infection [10, 44, 45, 47] ; these data
suggest this stealth strategy may also dramatically affect the kinetics of the T cell response. Our tularensis-specific CD8 + T cells produced IFN-γ upon stimulation (Fig 4) . We did not observe A major advantage of LVS-OVA is that it allows us to study pathogen-specific memory 4 4 7 development, particularly at times when cells of other specificities may be more abundant. We contraction and retention properties in various tissues following intranasal LVS infection (Fig 5) . to provide a rapid response that contributes to protection from reinfection, including against This suggests that lung T RM development is poor in this model, and that strategies to boost F. shown to be more virulent [10] . It is interesting to speculate that the increased protectiveness of vaccine responses will help to define correlates protective adaptive immunity. after an intranasal booster this difference was no longer evident. The intranasal booster also
increased the number of F. tularensis-specific CD8 + T cells in the lungs of scarification-primed
animals, but they did not lose any weight and tolerated the booster similarly to intranasal-primed
animals. One possible implication of these data is that a scarification-prime, respiratory-boost
strategy may achieve the same benefits as respiratory vaccination, with enhanced safety. . . 
